Oslo 26.02.2013 – The combination with complementary formulations aims to optimize future HIV treatments Bionor Pharma ASA (OSE: BIONOR) today announced that a new patent application relating to the Company`s HIV-vaccines Vacc-4x and Vacc-C5 has been submitted. The patent application contains claims covering various combinations of our vaccines with other agents such as immune modulators …
05.12.2012 – Final Approvals Received for International Study to Reboost Patients From the Completed Vacc-4x Phase II Trial Approximately 40 Patients Will Participate at 11 Clinics in USA and Europe News Summary * Study design: Open, clinical phase II study, with two Vacc-4x immunizations while patients remain on conventional HIV medication (Antiretroviral Therapy, ART), followed …
The rationale behind Bionor Pharma`s HIV vaccine research is presented by Dr. Jerry Zeldis from Celgene, and Prof. Gus Dalgleish, St. George`s University of London. Update on the Company – Steen Krøyer, CEO of Bionor Pharma Background for Bionor Pharma`s research cooperation with Celgene – Dr. Jerome “Jerry” Zeldis, CEO of Celgene Global Health and Chief Medical …
